| 101 |
NCT03372967 |
Recruiting |
Project IMPACT Immunizations (IMProving America's Communities Together) Scaled Demonstration |
|
- Biological: Vaccine administration by a pharmacist
- Behavioral: Unmet vaccination needs identified and met
- Behavioral: Vaccination forecast review and patient education
|
Observational |
|
- American Pharmacists Association Foundation
|
Other |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Change in vaccination rates for routinely recommended adult vaccinations
- Number of vaccines administered
- Types of vaccines administered
- Number of unmet vaccination needs that were identified and met
|
1000 |
All |
18 Years and older (Adult, Senior) |
NCT03372967 |
016 |
|
December 12, 2017 |
May 6, 2018 |
November 2, 2018 |
December 14, 2017 |
January 9, 2018 |
|
- Medicap Pharmacy
Carlisle, Iowa, United States - Eagle Pharmacy
Eagle Grove, Iowa, United States - Medicap Pharmacy
Eldora, Iowa, United States - (and 12 more...)
|
| 102 |
NCT03321968 |
Recruiting |
Lot-to-lot Consistency of a Plant-Derived Quadrivalent Virus-Like Particles Influenza Vaccine in Healthy Adults |
- Virus Diseases
- RNA Virus Infections
- Respiratory Tract Infections
- Respiratory Tract Disease
|
- Biological: Quadrivalent VLP Influenza Vaccine
|
Interventional |
Phase 3 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Single (Outcomes Assessor)
- Primary Purpose: Prevention
|
- Immunogenicity will be evaluated by the immune response, as measured by change from baseline of the serum HI antibody titers
- Number of subjects with immediate complaints following vaccination
- Number of subjects with solicited local and systemic signs and symptoms following vaccination
- (and 3 more...)
|
1200 |
All |
18 Years to 49 Years (Adult) |
NCT03321968 |
CP-PRO-QVLP-011 |
|
September 29, 2017 |
November 16, 2017 |
November 16, 2017 |
October 26, 2017 |
October 26, 2017 |
|
- Site 205
Halifax, Nova Scotia, Canada - Site 208
Burlington, Ontario, Canada - Site 207
Guelph, Ontario, Canada - (and 7 more...)
|
| 103 |
NCT03301051 |
Recruiting |
Efficacy, Safety, and Immunogenicity of a Plant-Derived Quadrivalent Virus-Like Particles Influenza Vaccine in Adults |
- Virus Diseases
- RNA Virus Infections
- Respiratory Tract Diseases
- Respiratory Tract Infections
|
- Biological: Quadrivalent VLP Vaccine
- Biological: Placebo
|
Interventional |
Phase 3 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Single (Outcomes Assessor)
- Primary Purpose: Prevention
|
- Time of occurence of protocol-defined respiratory illness due to laboratory-confirmed influenza caused by vaccine matched strains.
- Time of occurence of protocol-defined respiratory illness due to any laboratory-confirmed influenza strains.
- Number of subjects with solicited local and systemic reactions, unsolicited adverse events, serious adverse events and New Onset Chronic Diseases.
- Immunogenicity evaluated by the humoral immune response (HI, MN, and SRH assays) and the CMI response
|
10000 |
All |
18 Years to 64 Years (Adult) |
NCT03301051 |
CP-PRO-QVLP-012 |
|
August 31, 2017 |
April 30, 2018 |
April 30, 2018 |
October 4, 2017 |
October 4, 2017 |
|
- Site 222
Mobile, Alabama, United States - Site 210
Anaheim, California, United States - Site 223
Milford, Connecticut, United States - (and 70 more...)
|
| 104 |
NCT02148211 |
Recruiting |
Fluarix®/ FluLaval®/ Fluarix® Quadrivalent/ FluLaval® Quadrivalent Vaccine Pregnancy Registry |
|
|
Observational |
|
|
Industry |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Number of subjects reporting abnormal pregnancy outcomes in women intentionally or unintentionally vaccinated with Fluarix or FluLaval or Fluarix Quadrivalent or FluLaval Quadrivalent during pregnancy or within 28 days preceding conception.
|
1 |
Female |
Child, Adult, Senior |
NCT02148211 |
201476
EUPAS6521 |
|
June 1, 2014 |
June 1, 2019 |
June 1, 2019 |
May 28, 2014 |
March 6, 2018 |
|
- GSK Investigational Site
Wilmington, North Carolina, United States
|
| 105 |
NCT02989012 |
Not yet recruiting |
Phase IIaTrials of GanMaoKangNing Granules |
|
- Drug: GanMaoKangNing Granules
- Drug: Analogous Oseltamivir Phosphate Capsules
- Drug: Oseltamivir Phosphate Capsules
- Drug: Analogous GanMaoKangNing Granules
|
Interventional |
Phase 2 |
- Dalian Zhen-Ao Bio-Tech Co., Ltd.
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Flu recovery time
- Single symptom remission rate
- The antifebrile effect
|
96 |
All |
18 Years to 65 Years (Adult) |
NCT02989012 |
DalianZhen-Ao |
|
|
July 2019 |
|
December 12, 2016 |
December 12, 2016 |
|
- Beijing Hospital of Traditional Chinese Medicine Affiliated to Capital Medical University
Beijing Shi, Beijing, China
|
| 106 |
NCT03316768 |
Not yet recruiting |
Measurement of Grip and Pinch Forces Needed for Activities of Daily Living, Work and Prehistoric Stone Tool Production |
- Basilar Thumb Arthritis
- Wrist Fracture
- Measure Pressure Distribution and Resultant Forces Needed
|
|
Observational |
|
- Shaare Zedek Medical Center
|
Other |
- Observational Model: Case-Control
- Time Perspective: Prospective
|
|
54 |
All |
18 Years to 120 Years (Adult, Senior) |
NCT03316768 |
01D23E57.603E53E0 |
|
January 2018 |
December 2018 |
April 2019 |
October 20, 2017 |
October 20, 2017 |
|
|
| 107 |
NCT03277703 |
Recruiting |
Flu Vaccine Response in Patients on Biologic Therapies |
- Rheumatologic Disorder
- Inflammatory Bowel Diseases
- Immune Complex Diseases
|
- Biological: Influenza vaccine
|
Interventional |
Phase 2 |
- Stony Brook University
- University of North Carolina, Chapel Hill
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Prevention
|
- Influenza hemagglutination inhibition (HAI) titer
- Clinical efficacy of vaccine
|
54 |
All |
3 Years to 22 Years (Child, Adult) |
NCT03277703 |
1077651 |
|
November 3, 2017 |
April 2020 |
August 2020 |
September 11, 2017 |
April 18, 2018 |
|
- Clinical Research Center
East Setauket, New York, United States
|
| 108 |
NCT02957136 |
Recruiting |
Rapid Diagnostics for Upper Respiratory Infections in the Emergency Department |
- Respiratory Tract Infections
- Influenza, Human
- Common Cold
|
- Device: Rapid respiratory pathogen nucleic acid amplification test
|
Interventional |
Not Applicable |
- University of California, Davis
- BioFire Diagnostics, LLC
|
Other / Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Single (Outcomes Assessor)
- Primary Purpose: Health Services Research
|
- Proportion of patients receiving antibiotics or a prescription for antibiotics in the ED
- Proportion of patients with a respiratory pathogen identified
- Proportion of patients with a laboratory-confirmed influenza diagnosis
- (and 8 more...)
|
304 |
All |
1 Year to 101 Years (Child, Adult, Senior) |
NCT02957136 |
894097 |
URI DxED |
December 2016 |
May 2018 |
August 2018 |
November 7, 2016 |
December 19, 2017 |
|
- UC Davis Medical Center
Sacramento, California, United States
|
| 109 |
NCT02966470 |
Not yet recruiting |
Hand Grip Strength as a Marker of Frailty in Surgical Patients |
|
- Device: Obtain grip strength from a standardized gripometer
|
Observational |
|
|
Other |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- linear regression of grip strength to frailty survey score
|
100 |
All |
60 Years and older (Adult, Senior) |
NCT02966470 |
1609018398 |
|
February 2018 |
November 2018 |
November 2018 |
November 17, 2016 |
January 9, 2018 |
|
|
| 110 |
NCT03179761 |
Recruiting |
High vs. Standard Dose Flu Vaccine in Adult Stem Cell Transplant Recipients |
- Hematopoietic Cell Transplantation
|
- Biological: Quadrivalent Inactivated Influenza Vaccine
- Other: Laboratory Biomarker Analysis
- Biological: Trivalent Influenza Vaccine
|
Interventional |
Phase 2 |
- Vanderbilt-Ingram Cancer Center
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Prevention
|
- HD-TIV compared with SD-QIV (Influenza A) - immunogenicity
- HD-TIV compared with SD-QIV (Influenza B) - immunogenicity
- Solicited local injection site adverse events
- (and 3 more...)
|
138 |
All |
18 Years and older (Adult, Senior) |
NCT03179761 |
VICC BMT 1733
NCI-2017-00466 |
|
October 9, 2017 |
June 1, 2018 |
December 1, 2018 |
June 7, 2017 |
November 22, 2017 |
|
- University of Alabama
Birmingham, Alabama, United States - Northwestern University
Chicago, Illinois, United States - Vanderbilt-Ingram Cancer Center
Nashville, Tennessee, United States - Fred Hutchinson Cancer Center
Seattle, Washington, United States
|
| 111 |
NCT03056924 |
Recruiting |
Immunogenicity of Influenza, Pneumococcal and Hepatitis B Vaccines in IBD Patients Treated With Vedolizumab |
- Inflammatory Bowel Diseases
|
- Biological: Pneumococcal Pneumonia vaccine
- Biological: Influenza vaccine
- Biological: Hepatitis B vaccine
|
Observational |
|
|
Other |
- Observational Model: Case-Only
- Time Perspective: Prospective
|
- Rate of immune seroconversion after influenza, pneumococcal, or hepatitis B vaccine among the four groups of patients
|
400 |
All |
18 Years to 75 Years (Adult, Senior) |
NCT03056924 |
H-35669 |
|
July 5, 2017 |
June 30, 2018 |
June 30, 2018 |
February 17, 2017 |
July 12, 2017 |
|
- Boston Medical Center
Boston, Massachusetts, United States
|
| 112 |
NCT03053674 |
Not yet recruiting |
Impact of Explanation Given to Parents on Rate of Post-partum Influenza Vaccination |
|
- Other: Oral and written explanation
- Other: Follow-up questionnaire
|
Interventional |
Not Applicable |
- Hillel Yaffe Medical Center
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Prevention
|
- Rate of post-partum influenza vaccination
|
208 |
All |
Child, Adult, Senior |
NCT03053674 |
HYMC104-16 |
|
February 20, 2017 |
April 1, 2017 |
July 1, 2017 |
February 15, 2017 |
February 15, 2017 |
|
- Hillel Yaffe Medical Center
Hadera, Israel
|
| 113 |
NCT03501576 |
Recruiting
New |
Evaluation of Human Immune Responses to Influenza Virus Vaccination in Patients With Lymphoma |
- Chronic Lymphocytic Leukemia
- Diffuse Large B-Cell Lymphoma
- Follicular Lymphoma
- (and 2 more...)
|
- Biological: Inactivated Influenza Vaccine
|
Interventional |
Phase 1 |
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Prevention
|
- Percentage of subjects achieving seroprotection defined as the percentage of subjects with a post-vaccination hemagglutination inhibition (HI) titer > 1:40
- Percentage of subjects achieving seroconversion
- Measurement of influenza-specific serum antibody levels after influenza vaccination
- (and 3 more...)
|
100 |
All |
18 Years and older (Adult, Senior) |
NCT03501576 |
IRB00101067
NCI-2017-02313
Winship4236-17 |
|
April 6, 2018 |
April 30, 2021 |
April 30, 2021 |
April 18, 2018 |
April 18, 2018 |
|
- Emory University Hospital/Winship Cancer Institute
Atlanta, Georgia, United States
|
| 114 |
NCT02830828 |
Recruiting |
Studying Finger-thumb Grip in Patients With Carpal Tunnel Syndrome |
|
- Other: Investigation of precision pinch grip control
|
Observational |
|
- Thomas Edward Pidgeon
- University of Birmingham
- University Hospital Birmingham NHS Foundation Trust
|
Other |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Change in Precision Pinch Grip Force measured during a pinch-hold up activity over time during follow-up
|
35 |
All |
18 Years to 80 Years (Adult, Senior) |
NCT02830828 |
RRK5257 |
|
March 2015 |
September 2017 |
September 2017 |
July 13, 2016 |
June 6, 2017 |
|
- University Hospitals Birmingham Queen Elizabeth
Birmingham, West Midlands, United Kingdom
|
| 115 |
NCT03336593 |
Recruiting |
Protectivity and Safety of Quadrivalent Influenza HA Vaccine in Indonesian Population |
|
- Biological: Quadrivalent Influenza Vaccine
- Biological: Trivalent Influenza Vaccine
|
Interventional |
Phase 2 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Prevention
|
- Percentage of subjects with an anti-influenza titer >= 1:40 HI units
- Geometric Mean Titer (GMT)
- Percentage of subjects with increasing antibody titer >= 4 times
- (and 6 more...)
|
810 |
All |
6 Months to 40 Years (Child, Adult) |
NCT03336593 |
QIV 0217 |
|
November 21, 2017 |
April 2018 |
November 2018 |
November 8, 2017 |
March 6, 2018 |
|
- Garuda Primary Health Center
Bandung, West Java, Indonesia - Ibrahim Adjie Primary Health Center
Bandung, West Java, Indonesia - Puter Primary Health Center
Bandung, West Java, Indonesia
|
| 116 |
NCT03415425 |
Recruiting |
Using Rapid Cycle Randomized Controlled Trials to Optimize the Influenza Clinical Decision Support Tool |
- Clinical Decision Support
|
- Other: Current Version of the Influenza Alert
- Other: Alternate Modifications of the Influenza Alert
|
Interventional |
Not Applicable |
- New York University School of Medicine
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Health Services Research
|
- Alert Cancelation Rate
- Vaccination Rate at Discharge
|
4000 |
All |
3 Years and older (Child, Adult, Senior) |
NCT03415425 |
RCT CDS |
|
January 16, 2018 |
January 16, 2019 |
April 30, 2019 |
January 30, 2018 |
January 30, 2018 |
|
- New York University School of Medicine
New York, New York, United States
|
| 117 |
NCT02461758 |
Recruiting |
Trial of High Dose vs. Standard Dose Influenza Vaccine in Inflammatory Bowel Disease Patients |
- Inflammatory Bowel Disease (IBD)
|
- Biological: Influenza vaccine
|
Interventional |
Not Applicable |
- University of Wisconsin, Madison
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Prevention
|
- Measure antibody concentrations in immunosuppressed IBD patients who receive high dose and standard of care dose influenza vaccine
|
80 |
All |
18 Years to 64 Years (Adult) |
NCT02461758 |
2015-0813
Influenza in IBD |
|
October 2016 |
June 2018 |
June 2018 |
June 3, 2015 |
November 21, 2017 |
|
- University of Wisconsin Hospital & Clinics
Madison, Wisconsin, United States
|
| 118 |
NCT02765126 |
Recruiting |
Heterologous Effect of Diptheria, Tetanus, Acellular Pertussis Vaccination on Influenza Challenge in the Elderly |
- Heterologous Effects of Vaccines
|
- Biological: Seasonal influenza vaccine
- Biological: Diphtheria-tetanus-acellular pertussis vaccine
|
Interventional |
Not Applicable |
- Clifford Craig Medical Research Trust
- Monash University
- The Peter Doherty Institute for Infection and Immunity
- (and 2 more...)
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Basic Science
|
- Number of inflammation reactive TNFR2+ regulatory T cells per mL of blood
- Whole human genome transcription profile by next generation sequencing in log2 expression levels
- Influenza-specific antibody titres to seasonal influenza vaccination
- (and 2 more...)
|
450 |
All |
30 Years to 100 Years (Adult, Senior) |
NCT02765126 |
H0015460 |
|
May 2016 |
December 2019 |
December 2019 |
May 6, 2016 |
July 27, 2017 |
|
- Clifford Craig Foundation
Launceston, Tasmania, Australia
|
| 119 |
NCT02565277 |
Recruiting |
The Effect of Influenza Vaccination on the Systemic Inflammatory Response and Myocardial Protection in Patients Undergoing Cardiac Surgery: a Randomized Controlled Trial |
- Systemic Inflammatory Response
|
- Biological: Influenza Vaccine
- Drug: Placebo
|
Interventional |
Phase 4 |
- Health Sciences North Research Institute
|
Other |
- Allocation: Randomized
- Intervention Model: Crossover Assignment
- Masking: Double (Participant, Investigator)
|
- Pro and anti-inflammatory cytokines and inflammatory markers
|
150 |
All |
18 Years and older (Adult, Senior) |
NCT02565277 |
AMRIC Dr.Atoui |
|
September 2015 |
August 2017 |
August 2017 |
October 1, 2015 |
October 28, 2016 |
|
- Health Sciences North Research Institute
Sudbury, Ontario, Canada
|
| 120 |
NCT02414490 |
Recruiting |
IVIg Treatment-Related Fluctuations in CIDP Patients Using Daily Grip Strength Measurements |
- Chronic Inflammatory Demyelinating Polyneuropathy
|
- Drug: Intravenous Immunoglobulin
|
Observational |
|
- University of Minnesota - Clinical and Translational Science Institute
- AxelaCare Health Solutions, LLC
- CSL Behring
|
Other / Industry |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Daily grip strength (GS) measurements
- Percentage of IVIg treatment cycles in which the maximum and minimum grip strength (GS) measurements differ by more than 10% of the maximum
- Rasch-built Overall Disability Scale
- (and 3 more...)
|
30 |
All |
18 Years to 85 Years (Adult, Senior) |
NCT02414490 |
AHS1-13-001 |
GRIPPER |
March 2015 |
May 2018 |
May 2018 |
April 10, 2015 |
June 19, 2017 |
|
- Neurology at John's Creek
Johns Creek, Georgia, United States - Northwestern University
Chicago, Illinois, United States - University of Kansas Medical Center
Kansas City, Kansas, United States - (and 4 more...)
|
| 121 |
NCT02998736 |
Not yet recruiting |
Trial of Perioperative Tadalafil and Influenza Vaccination in Cancer Patients Undergoing Major Surgical Resection of a Primary Abdominal Malignancy |
|
- Drug: Cialis
- Biological: Influenza vaccine
|
Interventional |
Phase 1 |
- Ottawa Hospital Research Institute
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Prevention
|
- Determine the change in the number of regimen limiting toxicities (RLT) in the experimental cohort
- Document the change in the number and severity of CTCAE adverse events that are probably or definitely related to study treatment (tadalafil or influenza) in the experimental cohort.
- Compare the reduction in NK cell killing as measured on PBMC collected on SD1 as compared to baseline between the control and experimental cohorts, using a standard NK cell killing assay (51Chromium release assay).
|
24 |
All |
18 Years and older (Adult, Senior) |
NCT02998736 |
20160855-01H |
PERIOP-04 |
January 2017 |
January 2019 |
January 2020 |
December 20, 2016 |
December 20, 2016 |
|
|
| 122 |
NCT02519803 |
Not yet recruiting |
A Prospective Household Observational Cohort Study of Influenza, Respiratory Syncytial Virus and Other Respiratory Pathogens Community Burden and Transmission Dynamics in South Africa |
- Infective Organism Causing Respiratory Diseaseand Meningitis
|
|
Observational |
|
- National Institute for Communicable Diseases, South Africa
- Perinatal HIV Research Unit of the University of the Witswatersrand
|
Other |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Secondary attack rate of influenza and RSV
|
4500 |
All |
Child, Adult, Senior |
NCT02519803 |
PHIRST-SA |
PHIRST-SA |
January 2016 |
December 2018 |
December 2018 |
August 11, 2015 |
August 11, 2015 |
|
|
| 123 |
NCT03502707 |
Not yet recruiting
New |
A Study to Evaluate the Safety and Immunogenicity for Regimen Selection of Ad26.RSV.preF and/or RSV preF Protein Combinations Followed by Expanded Safety and Concomitant Influenza Vaccine Administration in Adults Aged 60 Years and Older |
|
- Biological: Placebo
- Biological: RSV preF Protein 50 mcg
- Biological: RSV preF Protein 150 mcg
- (and 7 more...)
|
Interventional |
Phase 1
Phase 2 |
- Janssen Vaccines & Prevention B.V.
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Prevention
|
- Cohorts 1 and 2: Number of Participants With Serious Adverse Events (SAEs)
- Cohort 3: Number of Participants With SAEs
- Cohorts 1 and 2: Number of Participants With Solicited Local and Systemic AEs for 7 Days After Each Vaccination
- (and 14 more...)
|
562 |
All |
60 Years and older (Adult, Senior) |
NCT03502707 |
CR108456
VAC18193RSV1004 |
|
May 11, 2018 |
July 31, 2018 |
December 17, 2020 |
April 19, 2018 |
April 19, 2018 |
|
- Optimal Research
Rockville, Maryland, United States
|
| 124 |
NCT02904304 |
Not yet recruiting |
Desloratadine,Phenylephrine Hcl,Ibuprofen Compared to Placebo in Treatment of Symptoms Associated With Common Cold/Flu |
|
- Drug: Desloratadine+Phenylephrine+Ibuprofen
- Drug: Placebo
|
Interventional |
Phase 3 |
- Ache Laboratorios Farmaceuticos S.A.
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Evaluation of the superiority of Desloratadine + Phenylephrine + Ibuprofen over placebo
- Evaluation of the symptoms related to the common cold / flu syndrome.
- Satisfaction of the quality of sleep
- (and 2 more...)
|
150 |
All |
18 Years to 65 Years (Adult) |
NCT02904304 |
ACH-DTN-03(02/16) |
|
August 2018 |
July 2019 |
November 2019 |
September 16, 2016 |
April 12, 2018 |
|
- Allergisa Pesquisa Dermato Cosmética Ltda.
Campinas, São Paulo, Brazil
|
| 125 |
NCT00471250 |
Recruiting |
Collection of Lung Fluid and Tissue Samples for Research |
- Mycobacterium Infections, Atypical
- Granulomatous Disease, Chronic
- Job's Syndrome
- Influenza, Human
|
|
Observational |
|
- National Heart, Lung, and Blood Institute (NHLBI)
- National Institutes of Health Clinical Center (CC)
|
NIH |
- Time Perspective: Prospective
|
|
550 |
All |
10 Years to 75 Years (Child, Adult, Senior) |
NCT00471250 |
070142
07-H-0142 |
|
May 7, 2007 |
|
|
May 9, 2007 |
April 4, 2018 |
|
- National Institutes of Health Clinical Center, 9000 Rockville Pike
Bethesda, Maryland, United States
|
| 126 |
NCT03400982 |
Not yet recruiting |
Reference Curve on Bone Mineral Density in Men |
- Bone Mineral Density
- Grip Strength
- Physical Performance
|
- Diagnostic Test: Bone densitometry measurement
|
Interventional |
Not Applicable |
- Centre Hospitalier Régional d'Orléans
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Other
|
- Bone mineral density of the spine
- Bone mineral density of the hip
- Fat mass of the body
- Lean mass of the body
|
200 |
Male |
20 Years to 30 Years (Adult) |
NCT03400982 |
CHRO-2017-10 |
COURDO2 |
April 2018 |
April 2019 |
April 2019 |
January 17, 2018 |
February 6, 2018 |
|
- CHU Amiens
Amiens, France - CHR d'Orléans
Orléans, France - Hopital Cochin
Paris, France - CHU de Saint Etienne
Saint-Étienne, France
|
| 127 |
NCT03316625 |
Recruiting |
Reference Curve on Bone Mineral Density in Young Adult: French Multicenter Study |
- Bone Mineral Density
- Grip Strength
- Physical Performance
|
- Diagnostic Test: Bone densitometry measurement
|
Interventional |
Not Applicable |
- Centre Hospitalier Régional d'Orléans
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Other
|
- bone mineral density of the spine
- bone mineral density of the hip
- body composition (fat mass, lean mass)
|
200 |
Male |
20 Years to 30 Years (Adult) |
NCT03316625 |
CHRO-2016-06 |
COURDO |
March 25, 2016 |
March 24, 2018 |
March 24, 2018 |
October 20, 2017 |
October 20, 2017 |
|
- Chru Lille
Lille, France - CHRU Lyon
Lyon, France - CHR Orléans
Orléans, France
|
| 128 |
NCT03183908 |
Recruiting |
FLUAD vs. Fluzone High-Dose Study |
- Pain
- Quality of Life
- Injection Site Reaction
- (and 2 more...)
|
- Biological: FLUAD
- Biological: Fluzone High-Dose
|
Interventional |
Phase 4 |
- Duke University
- Centers for Disease Control and Prevention
- Boston Medical Center
|
Other / U.S. Fed |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Investigator, Outcomes Assessor)
- Primary Purpose: Prevention
|
- Injection-Site Pain as Measured by visual analog scale
- Adverse Events of Clinical Interest
- Serious Adverse Events
- (and 9 more...)
|
900 |
All |
65 Years and older (Adult, Senior) |
NCT03183908 |
Pro00083845 |
|
August 28, 2017 |
September 2019 |
September 2019 |
June 12, 2017 |
September 26, 2017 |
|
- Centers for Disease Control and Prevention
Atlanta, Georgia, United States - Boston Medical Center
Boston, Massachusetts, United States - Duke University
Durham, North Carolina, United States
|
| 129 |
NCT02783170 |
Recruiting |
Safety and Immunogenicity of Simultaneous Tdap and IIV in Pregnant Women |
|
- Biological: Tetanus, Diphtheria, and Pertussis Vaccine
- Biological: 2016-2017 Quadrivalent Inactivated Influenza Vaccine
- Biological: 2017-2018 Quadrivalent Inactivated Influenza Vaccine
|
Interventional |
Phase 4 |
- Duke University
- Children's Hospital Medical Center, Cincinnati
- Centers for Disease Control and Prevention
|
Other / U.S. Fed |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Prevention
|
- Proportion of Injection-site Reactions post Tdap and Flu administration
- Proportions of Systemic Reactions post Tdap and Flu administration
- Pertussis Serum Antibody Levels, as measured by Geometric mean titers
- (and 16 more...)
|
80 |
Female |
18 Years to 45 Years (Adult) |
NCT02783170 |
Pro00071192 |
Tdap/IIV |
September 2016 |
September 2018 |
December 2018 |
May 26, 2016 |
December 4, 2017 |
|
- Centers for Disease Control and Prevention
Atlanta, Georgia, United States - Duke University
Durham, North Carolina, United States - Cincinnati Children's Hospital Medical Center
Cincinnati, Ohio, United States
|
| 130 |
NCT03247439 |
Recruiting |
Safety and Effectiveness of Cartiva Implant in the Treatment of First CMC Joint Osteoarthritis Compared to LRTI (GRIP 2) |
|
|
Interventional |
Not Applicable |
|
Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Pain measured by the Visual Analog Scale (VAS) scale
- Function measured by QuickDASH
- Radiographic Findings
- Safety
|
74 |
All |
22 Years and older (Adult, Senior) |
NCT03247439 |
PTC-0290 |
GRIP2 |
December 22, 2017 |
January 2023 |
January 2024 |
August 11, 2017 |
April 18, 2018 |
|
- Indiana Hand to Shoulder Center
Indianapolis, Indiana, United States - Tufts Medical Center
Boston, Massachusetts, United States - Hospital for Specialty Surgery
New York, New York, United States - (and 5 more...)
|
| 131 |
NCT03424733 |
Recruiting |
Evaluating the Use of Prednisone to Decrease Pegylated Interferon Beta-1a Side Effects |
|
- Drug: Plegridy
- Drug: Prednisone
- Drug: Tylenol Pill
|
Interventional |
Phase 4 |
- Holy Name Medical Center, Inc.
- Biogen
|
Other / Industry |
- Allocation: Non-Randomized
- Intervention Model: Crossover Assignment
- Masking: None (Open Label)
- Primary Purpose: Prevention
|
- Flu-like symptoms
- Injection site reactions
|
50 |
All |
18 Years and older (Adult, Senior) |
NCT03424733 |
US-PEG-16-10990 |
|
September 25, 2017 |
June 1, 2018 |
July 1, 2018 |
February 7, 2018 |
February 7, 2018 |
|
- Holy Name Medical Center
Teaneck, New Jersey, United States
|
| 132 |
NCT03347370 |
Recruiting |
A Post-Authorization Safety Study of Interferon Beta Therapy in Participants With Multiple Sclerosis |
- Multiple Sclerosis, Relapsing-Remitting
|
- Drug: SC Peginterferon beta-1a
- Drug: SC interferon beta-1a
- Drug: SC interferon beta-1b
|
Observational |
|
- Biogen
- AMS Advanced Medical Services GmbH
|
Industry / Other |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Percentage of Participants with at Least one Injection Site Reaction (ISR) as Reported by the Participants
- Percentage of Participants with at Least one Flu-like Symptoms (FLS) as Reported by the Participants
- Percentage of Participants with at Least one ISR (FLS) as Reported by the Nurse
- (and 9 more...)
|
1800 |
All |
18 Years and older (Adult, Senior) |
NCT03347370 |
GER-PEG-16-10988 |
PERFECT |
November 27, 2017 |
May 1, 2019 |
August 1, 2019 |
November 20, 2017 |
March 22, 2018 |
|
- Research Site
Göttingen, Germany
|
| 133 |
NCT03478254 |
Recruiting
New |
Adherence to Guidelines VAccination in Type 1 DIabetes Mellitus Patients (AVADI-1). |
|
- Biological: Influenza vaccination
- Biological: Pneumococcal vaccination
- Biological: Hepatitis B Virus (HBV) vaccination
|
Observational |
|
- Jesús Moreno Fernández
- Castilla-La Mancha Health Service
- University of Castilla-La Mancha
|
Other |
- Observational Model: Cohort
- Time Perspective: Cross-Sectional
|
- Adherence to regional guidelines for the immunization of adults with type 1 diabetes mellitus (T1DM
- Predictors of vaccination
- Relationship between adherence vaccination and related sick leaves
|
300 |
All |
18 Years and older (Adult, Senior) |
NCT03478254 |
C-127 |
AVADI-1 |
December 1, 2017 |
December 1, 2018 |
December 1, 2018 |
March 27, 2018 |
March 29, 2018 |
|
- Obispo Rafael Torija, St.
Ciudad Real, Spain
|
| 134 |
NCT02422264 |
Recruiting |
Immunogenicity and Safety Study of Infanrix Hexa in Healthy Infants Born to Mothers Vaccinated With Boostrix™ During Pregnancy or Immediately Post-delivery |
- Acellular Pertussis
- Tetanus
- Poliomyelitis
- Diphtheria
|
- Biological: Infanrix hexa
- Drug: Prevnar13
|
Interventional |
Phase 4 |
|
Industry |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Prevention
|
- Vaccine response to PT, FHA and PRN antigens
- Number of seroprotected subjects for anti-diphtheria (anti-D) and anti-tetanus (anti-T).
- Number of seroprotected subjects for anti-HBs.
- (and 14 more...)
|
622 |
All |
6 Weeks to 14 Weeks (Child) |
NCT02422264 |
201330
2014-001117-41 |
|
January 22, 2016 |
April 17, 2018 |
April 17, 2018 |
April 21, 2015 |
November 14, 2017 |
|
- GSK Investigational Site
Carlton, Victoria, Australia - GSK Investigational Site
Calgary, Alberta, Canada - GSK Investigational Site
Halifax, Nova Scotia, Canada - (and 28 more...)
|
| 135 |
NCT01163357 |
Recruiting |
Bortezomib, Total Marrow Irradiation, Fludarabine Phosphate, and Melphalan in Treating Patients Undergoing Donor Peripheral Blood Stem Cell Transplant For High-Risk Stage I or II Multiple Myeloma |
- Refractory Multiple Myeloma
- Stage I Multiple Myeloma
- Stage II Multiple Myeloma
|
- Drug: bortezomib
- Drug: fludarabine phosphate
- Other: melphalan
- (and 5 more...)
|
Interventional |
Phase 1 |
- City of Hope Medical Center
- National Cancer Institute (NCI)
|
Other / NIH |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Maximum tolerated dose of bortezomib as defined as the highest dose tested in which none or only one patient experiences dose limiting toxicity attributable to the study regimen
- Feasibility of escalating doses of bortezomib with or without TMI in combination with FLU and MEL as preparative regimen for allogeneic hematopoietic stem cell transplant in patients with high risk multiple myeloma
- Frequency of clinical response (i.e., complete, partial, or very good partial response)
- (and 6 more...)
|
27 |
All |
18 Years to 70 Years (Adult, Senior) |
NCT01163357 |
09171
NCI-2010-01610 |
|
January 28, 2011 |
September 2018 |
September 2018 |
July 15, 2010 |
February 8, 2018 |
|
- City of Hope
Duarte, California, United States
|
| 136 |
NCT03239665 |
Recruiting |
Vaccination Education Through Pharmacists and Senior Centers (VEPSC) |
- Infectious Disease
- Pneumonia, Bacterial
- Influenza
- Zoster; Herpes
|
- Behavioral: Pharmacist-led Intervention (PHARM)
- Behavioral: Peer-led Intervention (PEER)
|
Interventional |
Not Applicable |
- Rutgers, The State University of New Jersey
- Merck Sharp & Dohme Corp.
- Thomas Jefferson University
|
Other / Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Prevention
|
- Mean change in knowledge as assessed by the knowledge instrument score
- Mean change in beliefs as assessed by responses to the beliefs inventory
- Cost analysis
- (and 2 more...)
|
316 |
All |
50 Years and older (Adult, Senior) |
NCT03239665 |
Pro20170000208 |
VEPSC |
October 10, 2017 |
August 2018 |
August 2018 |
August 4, 2017 |
November 17, 2017 |
|
- Rutgers University
Piscataway, New Jersey, United States
|
| 137 |
NCT03169699 |
Recruiting |
Acoustic Analytic Apps for Smart Telehealth Screening - Creating a Big Data |
- URTI
- Cough
- Cough Variant Asthma
- Cough; Bronchial, With Grippe or Influenza
|
|
Observational |
|
- KK Women's and Children's Hospital
- Singapore University of Technology and Design
|
Other |
- Observational Model: Case-Control
- Time Perspective: Prospective
|
- Acute phase acoustic spectrum Analysis
- Recovery or Chronic phase acoustic spectrum analysis
|
600 |
All |
up to 16 Years (Child) |
NCT03169699 |
KKWCH 2016/2416 |
|
February 1, 2017 |
March 31, 2018 |
March 31, 2018 |
May 30, 2017 |
June 1, 2017 |
|
- KKWCH
Singapore, Singapore
|
| 138 |
NCT03228095 |
Not yet recruiting |
Volatiles in Breath and Headspace Analysis - Diagnostic Markers |
- Tuberculosis
- Gastric Cancer
- Peptic Ulcer
- (and 13 more...)
|
- Diagnostic Test: VOC detection in breath and in skin headspace
- Diagnostic Test: Breath sampling
- Procedure: Upper endoscopy with biopsies
- (and 5 more...)
|
Observational |
|
- University of Latvia
- Technion, Israel Institute of Technology
- Riga East University Hospital
- JLM Innovation GmbH
|
Other |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Specific VOC detected
- Performance of nanoarray sensor testing to detect target lesions and diseases
- Specific VOC patterns for target disease or lesion and risk groups
- (and 3 more...)
|
3000 |
All |
18 Years and older (Adult, Senior) |
NCT03228095 |
2017/20329 |
Volatolome |
July 24, 2017 |
December 20, 2019 |
December 31, 2025 |
July 24, 2017 |
July 26, 2017 |
|
- University of Latvia
Riga, Latvia
|
| 139 |
NCT02853929 |
Recruiting |
Evaluation of Immunogenicity and Safety of a Booster Dose of Infanrix Hexa™ in Healthy Infants Born to Mothers Vaccinated With Boostrix™ During Pregnancy or Immediately Post-delivery |
- Diphtheria
- Hepatitis B
- Acellular Pertussis
- (and 3 more...)
|
- Biological: Infanrix hexa
|
Interventional |
Phase 4 |
|
Industry |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Prevention
|
- Number of seroprotected subjects for anti-diphtheria, anti-tetanus, anti-HBs, anti-poliovirus type 1, anti-poliovirus type 2, anti-poliovirus type 3 and anti-polyribosyl-ribitol phosphate.
- Number of subjects with a booster response to PT, FHA and PRN antigens.
- Number of seroprotected subjects against anti-diphtheria, anti-tetanus, anti-poliovirus type 1, anti-poliovirus type 2, anti-poliovirus type 3, anti-HBs and anti-PRP.
- (and 7 more...)
|
555 |
All |
9 Months to 19 Months (Child) |
NCT02853929 |
201334
2014-001120-30 |
|
September 19, 2016 |
March 14, 2019 |
March 14, 2019 |
August 3, 2016 |
April 20, 2018 |
|
- GSK Investigational Site
Carlton, Victoria, Australia - GSK Investigational Site
Calgary, Alberta, Canada - GSK Investigational Site
Halifax, Nova Scotia, Canada - (and 26 more...)
|
| 140 |
NCT02554188 |
Not yet recruiting |
Fasting-mimicking Diet and Immunosenescence |
|
- Biological: Seasonal influenza (flu) vaccine
- Other: Diet
|
Interventional |
Phase 2 |
- University of Southern California
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Single (Outcomes Assessor)
- Primary Purpose: Basic Science
|
- Anti-Influenza Serum antibody titers 4 weeks after flu vaccination
- Body composition changes
- Physiological changes
- (and 3 more...)
|
320 |
All |
50 Years to 75 Years (Adult, Senior) |
NCT02554188 |
HS-16-00467 |
|
May 1, 2018 |
October 1, 2019 |
December 1, 2019 |
September 18, 2015 |
March 31, 2017 |
|
|
| 141 |
NCT02972281 |
Recruiting |
Systematic Search for Primary Immunodeficiency in Adults With Infections |
- Complement Deficiency
- Antibody Deficiency
- Chronic Sinus Infection
- (and 7 more...)
|
- Biological: Immunological diagnosis tests
|
Interventional |
Not Applicable |
- University Hospital, Lille
- Imagine Institute
- Octapharma
- (and 4 more...)
|
Other / Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Diagnostic
|
- Frequency of Primary immunodeficiencies (PIDs) in adult patients with recurrent and/or severe bacterial infection with encapsulated bacteria
|
240 |
All |
18 Years to 65 Years (Adult) |
NCT02972281 |
2014_07
2014-A00739-38 |
SPIDAC |
March 2015 |
March 2018 |
March 2018 |
November 23, 2016 |
December 22, 2017 |
|
|
| 142 |
NCT03341195 |
Not yet recruiting |
Mobile Phone SMS Messages and Automated Calls in Improving Vaccine Coverage Among Children in Pakistan |
- Tuberculosis
- Polio
- Diphtheria
- (and 5 more...)
|
- Behavioral: SMS messages and automated calls
|
Interventional |
Not Applicable |
- Aga Khan University
- Grand Challenges Canada
- University of British Columbia
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Prevention
|
- The primary outcome will measure the number of children who got vaccinated for routine immunization scheduled at 6, 10 and 14 weeks of life
- The secondary outcome will measure the mean improvement in on-time vaccination for routine immunization scheduled at 6, 10 and 14 weeks of life
|
3850 |
All |
up to 14 Days (Child) |
NCT03341195 |
4320-Ped_ERC-16 |
|
January 2018 |
July 2018 |
September 2018 |
November 14, 2017 |
November 17, 2017 |
|
|
| 143 |
NCT02898688 |
Recruiting |
P3+ Intervention Phase |
|
- Behavioral: Control Site
- Behavioral: Intervention Site
- Behavioral: Patient-level Control Group
- Behavioral: Patient-level Intervention Group
|
Interventional |
Not Applicable |
- Emory University
- National Institute of Allergy and Infectious Diseases (NIAID)
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Factorial Assignment
- Masking: None (Open Label)
- Primary Purpose: Health Services Research
|
- Number of women receiving influenza vaccination
- Number of women receiving pertussis vaccination
- Timely childhood vaccinations
- (and 3 more...)
|
1896 |
Female |
18 Years to 50 Years (Adult) |
NCT02898688 |
IRB00090267
5R01AI110482-02 |
|
June 12, 2017 |
December 2019 |
December 2019 |
September 13, 2016 |
July 19, 2017 |
|
- CU Center for Midwifery
Aurora, Colorado, United States - CU Maternal and Fetal Medicine Clinic
Aurora, Colorado, United States - University Nurse Midwives
Aurora, Colorado, United States - (and 20 more...)
|
| 144 |
NCT03165981 |
Recruiting |
Fever After Simultaneous Versus Sequential Vaccination in Young Children |
- Fever After Vaccination
- Fever
- Febrile Seizure
|
- Biological: PCV13
- Biological: DTaP
- Biological: IIV
|
Interventional |
Phase 4 |
- Duke University
- Centers for Disease Control and Prevention
- Kaiser Permanente
|
Other / U.S. Fed |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Prevention
|
- Occurrence of Fever following Vaccination
- Occurrence of Fever Visit 1
- Occurrence of Fever Visit 2
- (and 9 more...)
|
280 |
All |
12 Months to 16 Months (Child) |
NCT03165981 |
Pro00082484
200 2012 53663 0009 |
|
August 25, 2017 |
June 2018 |
June 2018 |
May 24, 2017 |
April 17, 2018 |
|
- Kaiser Permanente Northern California
Oakland, California, United States - Centers for Disease Control and Prevention
Atlanta, Georgia, United States - Duke University
Durham, North Carolina, United States
|
| 145 |
NCT03449459 |
Not yet recruiting |
Prevention of Acute Exacerbation in Subjects With COPD by Bacterial Decolonization in Lower Respiratory Tract |
- Chronic Obstructive Pulmonary Disease (COPD)
|
- Dietary Supplement: oral probiotics
- Drug: aerosol inhaled amikacin
- Biological: combined vaccination
|
Interventional |
Early Phase 1 |
- Shanghai Zhongshan Hospital
- The First Affiliated Hospital of Guangzhou Medical University
- Ruijin Hospital
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Prevention
|
- Time to the first COPD exacerbation
- Colonization of potential pathogenic bacteria in induced sputum
- Microbiome in induced sputum
- (and 8 more...)
|
144 |
All |
18 Years to 65 Years (Adult) |
NCT03449459 |
B2017-197R
2017YFC1309303 |
PAEAN |
July 2018 |
December 2020 |
December 2020 |
February 28, 2018 |
February 28, 2018 |
|
- The First Affiliated Hospital of Guangzhou Medical University
Guangzhou, Guangdong, China - Ruijin Hospital, Shanghai Jiao Tong University
Shanghai, Shanghai, China - Shanghai Zhongshan Hospital
Shanghai, Shanghai, China
|
| 146 |
NCT03457194 |
Not yet recruiting |
Optimising Protection for Pregnant Women and Infants With Maternal Vaccination |
|
- Biological: Quadrivalent Influenza Vaccine
- Biological: DTP Vaccine (Multiple Actives)
|
Observational |
|
- Women's and Children's Hospital, Australia
- Sanofi Pasteur, a Sanofi Company
|
Other / Industry |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Immunogenicity against the 4 influenza strains included in the 2017-2019 Southern Hemisphere Influenza vaccine pre and post vaccination in obese and non-obese women
- Antibodies to pertussis antigens
- Persistence of antibodies to pertussis antigens
- Persistence of antibodies to the 4 influenza strains included in the 2017-2019
|
150 |
Female |
18 Years and older (Adult, Senior) |
NCT03457194 |
HREC/17/WCHN/63 |
OPTIWIN |
May 1, 2018 |
December 2020 |
May 30, 2021 |
March 7, 2018 |
March 7, 2018 |
|
|
| 147 |
NCT03150823 |
Not yet recruiting |
Effectiveness of the Upstream and Downstream Direct Current on the Handgrip Strength |
|
- Procedure: Upward Direct Current (Ascending Effect)
- Procedure: Downward Direct Current (Descending Effect)
- Procedure: Sham Direct Current
|
Interventional |
Not Applicable |
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Care Provider, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Difference of Maximum handgrip force
- Difference of Maximum Electromiographic Activation Threshold
|
200 |
All |
18 Years and older (Adult, Senior) |
NCT03150823 |
6031205 |
|
April 26, 2018 |
April 26, 2018 |
May 2, 2018 |
May 12, 2017 |
April 10, 2018 |
|
|
| 148 |
NCT02806765 |
Recruiting |
Effect of Dietary Supplementation on Dynamic Stability |
|
- Dietary Supplement: (1S,3Z)-3-[(2E)-2-[(1R,3aS,7aR)-7a-methyl-1-[(2R)-6-methylheptan-2-yl]-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]-4-methylidenecyclohexan-1-ol
- Other: Control
|
Interventional |
Not Applicable |
- Arizona State University
- Abbott Nutrition
- DSM Nutritional Products, Inc.
- (and 2 more...)
|
Other / Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Care Provider, Investigator)
- Primary Purpose: Basic Science
|
- Dynamic Stability, change from baseline
- Postural Stability, change from baseline
- Gait Speed, change from baseline
- (and 2 more...)
|
70 |
All |
65 Years to 95 Years (Adult, Senior) |
NCT02806765 |
ANAM1308 |
|
April 2016 |
December 2016 |
June 2018 |
June 21, 2016 |
June 28, 2016 |
|
- Glencroft Senior Living: Retirement Community in Arizona
Glendale, Arizona, United States
|
| 149 |
NCT03443427 |
Recruiting |
A Study to Test if a Third Dose of the Vaccine is Safe in Current and Former Smokers Aged 40 to 80 Years Old and to Gather Information on the Immune Response Following the Third Dose of the Vaccine |
|
- Biological: NTHi Mcat investigational vaccine (GSK3277511A)
- Biological: Placebo
|
Interventional |
Phase 2 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Prevention
|
- Number of subjects reported with each solicited local adverse event (AE) (any and grade 3) within each vaccination schedule.
- Number of subjects reported with each solicited general adverse event (AE) (any and grade 3) within each vaccination schedule.
- Number of subjects reported with any unsolicited adverse event (AE) within each vaccination schedule.
- (and 12 more...)
|
200 |
All |
40 Years to 80 Years (Adult, Senior) |
NCT03443427 |
207759
2017-002941-31 |
|
March 20, 2018 |
June 29, 2020 |
June 29, 2020 |
February 23, 2018 |
April 10, 2018 |
|
- GSK Investigational Site
Truro, Nova Scotia, Canada - GSK Investigational Site
Sherbrooke, Quebec, Canada - GSK Investigational Site
Wuerzburg, Bayern, Germany - (and 5 more...)
|
| 150 |
NCT01431326 |
Recruiting |
Pharmacokinetics of Understudied Drugs Administered to Children Per Standard of Care |
- Adenovirus
- Anesthesia
- Anxiety
- (and 47 more...)
|
- Drug: The POPS study is collecting PK data on children prescribed the following drugs of interest per standard of care:
|
Observational |
|
- Daniel Benjamin
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
- The EMMES Corporation
- Duke University
|
Other / NIH / Industry |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Composite of pharmacokinetic outcomes for understudied drugs in children
- Composite pharmacodynamic outcomes of understudied drugs in children
- Biomarkers associated with understudied drugs in children
|
10000 |
All |
up to 21 Years (Child, Adult) |
NCT01431326 |
Pro00029638
IND 113645
IND 114369
IND 114531
IND 118358
HHSN20100006
HHSN27500020
HHSN27500027
HHSN27500043
HHSN27500049 |
PTN_POPS |
November 2011 |
February 2020 |
February 2020 |
September 9, 2011 |
April 4, 2018 |
|
- Alaska Native Medical Center
Anchorage, Alaska, United States - Arkansas Children's Hospital
Little Rock, Arkansas, United States - University of California at San Diego Medical Center
La Jolla, California, United States - (and 51 more...)
|
Create an RSS feed from your search for:
Download the search results for: